ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Merus NV

Merus NV (MRUS)

44.75
-0.16
(-0.36%)
Closed March 27 04:00PM
44.75
0.00
( 0.00% )
Pre Market: 08:39AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
44.75
Bid
44.76
Ask
50.65
Volume
-
0.00 Day's Range 0.00
17.15 52 Week Range 52.035
Market Cap
Previous Close
44.75
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
600,502
Shares Outstanding
57,878,284
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Merus NV

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

Sector
Gen Med & Surgical Hospitals
Industry
Gen Med & Surgical Hospitals
Website
Headquarters
Utrecht, Utrecht, Nld
Founded
1970
Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $44.75. Over the last year, Merus NV shares have traded in a share price range of $ 17.15 to $ 52.035.

Merus NV currently has 57,878,284 shares outstanding.

MRUS Latest News

Form 8-K - Current report

NL 00-0000000 false 0001651311 0001651311 2024-03-05 2024-03-05     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K    ...

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a...

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Table of Contents As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. 333-            UNITED STATES...

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No...

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.19-2.5903352198545.9447.58994446770145.83130576CS
4-5.07-10.176635889249.8252.03543.3966645147.04953984CS
1216.8960.624551328127.8652.03527.7260050241.41855445CS
2619.7178.71405750825.0452.03519.80550402633.45492776CS
5226.82149.58170663717.9352.03517.1543310628.70729315CS
15623.77113.29837940920.9852.03512.0333862325.19837967CS
26032.01251.2558869712.7452.03510.1824073023.86896963CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 20.75
(336.84%)
2.22M
XLOXilio Therapeutics Inc
$ 1.99
(211.42%)
9.04M
AKANAkanda Corporation
$ 0.3235
(96.18%)
15.48M
PIKKidpik Corporation
$ 6.19
(89.30%)
4.04M
BCGBinah Capital Group Inc
$ 15.50
(63.16%)
190.9k
NCNANuCana PLC
$ 0.24
(-21.73%)
128.95k
GMDAGamida Cell Ltd
$ 0.047
(-20.61%)
8.02M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
11
MLKNMillerKnoll Inc
$ 24.91
(-18.41%)
72.25k
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
320
KTRAKintara Therapeutics Inc
$ 0.1062
(18.66%)
18.24M
AKANAkanda Corporation
$ 0.3235
(96.18%)
15.6M
AKBAAkebia Therapeutics Inc
$ 2.48
(10.71%)
12.83M
CISSC3is Inc
$ 0.0334
(-12.57%)
12.19M
XLOXilio Therapeutics Inc
$ 1.97
(208.29%)
9.07M

Your Recent History

Delayed Upgrade Clock